Immunotherapy in microsatellite instability-high and microsatellite stable colorectal cancer

Colorectal cancer (CRC) is genetically heterogeneous, particularly with regard to microsatellite stability, which significantly impacts treatment outcomes. Immunotherapy has emerged as a cornerstone in treating CRC, especially for cases with high microsatellite instability (MSI-H). However, microsatellite stable (MSS) CRC, which comprises the majority of cases, presents challenges due to its lower mutational burden and the immunosuppressive nature of its tumor microenvironment. Current research focuses on combination therapies and improving immunomodulatory strategies, such as targeting immune-suppressive cells or factors within the tumor microenvironment, to enhance the effectiveness of immunotherapy for MSS CRC and identify effective biomarkers. In this review, we searched Web of Science, PubMed (MEDLINE), Google Scholar, Embase, Cochrane Library, Science Direct, Scopus, and Springer Link to identify relevant studies up to October 2024. This review addresses these gaps by evaluating contemporary therapeutic strategies for MSS and MSI-H CRC, focusing on combination approaches designed to augment the efficacy of immune checkpoint inhibitors.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-11-21
DOI
https://doi.org/10.1007/s12672-026-04936-y
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immunotherapy in microsatellite instability-high and microsatellite stable colorectal cancer

Jinmiao Wang, Tianzuo Wang, Xiao Hu, Boshi Duan et al.
Discover Oncology
Cancer Immunotherapy and Biomarkers
article

Immunotherapy in microsatellite instability-high and microsatellite stable colorectal cancer

Jinmiao Wang, Tianzuo Wang, Xiao Hu, Boshi Duan, Shupei Li, Xue Bai, Tianyou Wang
article en

Abstract

Colorectal cancer (CRC) is genetically heterogeneous, particularly with regard to microsatellite stability, which significantly impacts treatment outcomes. Immunotherapy has emerged as a cornerstone in treating CRC, especially for cases with high microsatellite instability (MSI-H). However, microsatellite stable (MSS) CRC, which comprises the majority of cases, presents challenges due to its lower mutational burden and the immunosuppressive nature of its tumor microenvironment. Current research focuses on combination therapies and improving immunomodulatory strategies, such as targeting immune-suppressive cells or factors within the tumor microenvironment, to enhance the effectiveness of immunotherapy for MSS CRC and identify effective biomarkers. In this review, we searched Web of Science, PubMed (MEDLINE), Google Scholar, Embase, Cochrane Library, Science Direct, Scopus, and Springer Link to identify relevant studies up to October 2024. This review addresses these gaps by evaluating contemporary therapeutic strategies for MSS and MSI-H CRC, focusing on combination approaches designed to augment the efficacy of immune checkpoint inhibitors.

Discover Oncology
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), National Cancer Center (US), Suizhou Central Hospital (CN), University of Hong Kong - Shenzhen Hospital (CN)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon